Cargando…

Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?

Stereotactic ablative body radiotherapy (SABR) is an effective technique comparable to surgery in terms of local control and efficacy in early stages of non-small cell lung cancer (NSCLC) and pulmonary metastasis. Several fractionation schemes have proven to be safe and effective, including the sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández, Castalia, Navarro-Martin, Arturo, Bobo, Andrea, Cabrera-Rodriguez, Joaquín, Calvo, Patricia, Chicas-Sett, Rodolfo, Luna, Javier, Rodríguez de Dios, Nuria, Couñago, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894272/
https://www.ncbi.nlm.nih.gov/pubmed/35316929
http://dx.doi.org/10.5306/wjco.v13.i2.101
_version_ 1784662617561759744
author Fernández, Castalia
Navarro-Martin, Arturo
Bobo, Andrea
Cabrera-Rodriguez, Joaquín
Calvo, Patricia
Chicas-Sett, Rodolfo
Luna, Javier
Rodríguez de Dios, Nuria
Couñago, Felipe
author_facet Fernández, Castalia
Navarro-Martin, Arturo
Bobo, Andrea
Cabrera-Rodriguez, Joaquín
Calvo, Patricia
Chicas-Sett, Rodolfo
Luna, Javier
Rodríguez de Dios, Nuria
Couñago, Felipe
author_sort Fernández, Castalia
collection PubMed
description Stereotactic ablative body radiotherapy (SABR) is an effective technique comparable to surgery in terms of local control and efficacy in early stages of non-small cell lung cancer (NSCLC) and pulmonary metastasis. Several fractionation schemes have proven to be safe and effective, including the single fraction (SF) scheme. SF is an option cost-effectiveness, more convenience and comfortable for the patient and flexible in terms of its management combined with systemic treatments. The outbreak of the severe acute respiratory syndrome coronavirus 2 pandemic has driven this not new but underutilized paradigm, recommending this option to minimize patients’ visits to hospital. SF SABR already has a long experience, strong evidence and sufficient maturity to reliably evaluate outcomes in peripheral primary NSCLC and there are promising outcomes in pulmonary metastases, making it a valid treatment option; although its use in central locations, synchronous and recurrencies tumors requires more prospective safety and efficacy studies. The SABR radiobiology study, together with the combination with systemic therapies, (targeted therapies and immunotherapy) is a direction of research in both advanced disease and early stages whose future includes SF.
format Online
Article
Text
id pubmed-8894272
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-88942722022-03-21 Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm? Fernández, Castalia Navarro-Martin, Arturo Bobo, Andrea Cabrera-Rodriguez, Joaquín Calvo, Patricia Chicas-Sett, Rodolfo Luna, Javier Rodríguez de Dios, Nuria Couñago, Felipe World J Clin Oncol Minireviews Stereotactic ablative body radiotherapy (SABR) is an effective technique comparable to surgery in terms of local control and efficacy in early stages of non-small cell lung cancer (NSCLC) and pulmonary metastasis. Several fractionation schemes have proven to be safe and effective, including the single fraction (SF) scheme. SF is an option cost-effectiveness, more convenience and comfortable for the patient and flexible in terms of its management combined with systemic treatments. The outbreak of the severe acute respiratory syndrome coronavirus 2 pandemic has driven this not new but underutilized paradigm, recommending this option to minimize patients’ visits to hospital. SF SABR already has a long experience, strong evidence and sufficient maturity to reliably evaluate outcomes in peripheral primary NSCLC and there are promising outcomes in pulmonary metastases, making it a valid treatment option; although its use in central locations, synchronous and recurrencies tumors requires more prospective safety and efficacy studies. The SABR radiobiology study, together with the combination with systemic therapies, (targeted therapies and immunotherapy) is a direction of research in both advanced disease and early stages whose future includes SF. Baishideng Publishing Group Inc 2022-02-24 2022-02-24 /pmc/articles/PMC8894272/ /pubmed/35316929 http://dx.doi.org/10.5306/wjco.v13.i2.101 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Fernández, Castalia
Navarro-Martin, Arturo
Bobo, Andrea
Cabrera-Rodriguez, Joaquín
Calvo, Patricia
Chicas-Sett, Rodolfo
Luna, Javier
Rodríguez de Dios, Nuria
Couñago, Felipe
Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?
title Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?
title_full Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?
title_fullStr Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?
title_full_unstemmed Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?
title_short Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?
title_sort single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: a new paradigm?
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894272/
https://www.ncbi.nlm.nih.gov/pubmed/35316929
http://dx.doi.org/10.5306/wjco.v13.i2.101
work_keys_str_mv AT fernandezcastalia singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm
AT navarromartinarturo singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm
AT boboandrea singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm
AT cabrerarodriguezjoaquin singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm
AT calvopatricia singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm
AT chicassettrodolfo singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm
AT lunajavier singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm
AT rodriguezdediosnuria singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm
AT counagofelipe singlefractionstereotacticablativebodyradiationtherapyforprimaryandmetastasiclungtumoranewparadigm